NCT05198401

Brief Summary

Whilst the global COVID-19 pandemic is still evolving and there are many unknowns about the long-term effects of the virus on fertility and pregnancy, we found ourselves in need to offer some evidence-based guidance, that's why we decided to go for this study, to evaluate the relation of the covid-19 and the outcome of IVF/ICSI cycles. we found that there is no clear evidence that the previous exposure to Covid-19 virus infection can affect the outcome of ICSI cycles significantly.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
122

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 2, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 2, 2021

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 15, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 20, 2022

Completed
Last Updated

January 20, 2022

Status Verified

January 1, 2022

Enrollment Period

9 months

First QC Date

January 15, 2022

Last Update Submit

January 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of mature oocytes (MII)

    how many mature oocytes

    10 days

Secondary Outcomes (2)

  • total number of blastocysts

    15 days

  • B-hcg

    4 weeks

Study Arms (2)

1

(previous covid-19 positive) n. =88

Other: covid-19

2

(covid-19 negative) n.=91

Interventions

viral infection

1

Eligibility Criteria

Age20 Years - 38 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

All women underwent individualized antagonist protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kamal Eldin Abdalla Rageh

Cairo, 15006, Egypt

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
9 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 15, 2022

First Posted

January 20, 2022

Study Start

August 1, 2020

Primary Completion

May 2, 2021

Study Completion

May 2, 2021

Last Updated

January 20, 2022

Record last verified: 2022-01

Locations